Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.
|
28871472 |
2017 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Allelic variation at the CYP2D6 gene has been reported to be associated with Parkinsons' disease (PD) and Lewy body dementia (LBD), but not with Alzheimer's disease (AD).
|
10071712 |
1999 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Allelic variation at the CYP2D6 gene has been suggested to be associated with CNS disorders, including Parkinson's disease and Lewy body dementia.
|
16337409 |
2006 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although some characteristic patterns of the combined genotypes were observed in both PD patients and controls, a strong association between the heterogeneity of the CYP2D6 gene and PD was not shown by combined genotype analysis.
|
9440484 |
1998 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although they are based on a small group of subjects with the joint exposure, our findings are consistent with a gene-environment interaction disease model according to which (1) pesticides have a modest effect in subjects who are not CYP2D6 poor metabolizers, (2) pesticides' effect is increased in poor metabolizers (approximately twofold), and (3) poor metabolizers are not at increased PD risk in the absence of pesticide exposure.
|
14991823 |
2004 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Although they are based on a small group of subjects with the joint exposure, our findings are consistent with a gene-environment interaction disease model according to which (1) pesticides have a modest effect in subjects who are not CYP2D6 poor metabolizers, (2) pesticides' effect is increased in poor metabolizers (approximately twofold), and (3) poor metabolizers are not at increased PD risk in the absence of pesticide exposure.
|
14991823 |
2004 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analyses of the cytochrome P450 CYP2D6-debrisoquine 4-hydroxylase mutant B allele, a susceptibility gene for PD, revealed a higher representation of this allele in the Lewy body variant of AD than in pure AD or non-AD without Lewy bodies.
|
7818242 |
1995 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As yet, there is no conclusive evidence to suggest that CYP2D6 polymorphisms confer susceptibility to PD.
|
9539332 |
1998 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
By contrast with the common occurrence of polymorphism of the CYP2D6 gene (a gene involved with xenobiotic metabolism) in white people, it is very rare in China and is not thought to be a significant factor contributing to Parkinson's disease in Chinese people.
|
9810958 |
1998 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians.
|
10210913 |
1999 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Data from our group and others suggest that the CYP2D6 PM genotype interacts with certain environmental factors such as pesticide exposure and cigarette smoking to confer differential risk for PD.
|
17017524 |
2006 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Despite several recent meta-analyses showing an association between several polymorphisms in genes related with detoxification mechanisms such as cytochrome P4502D6 (CYP2D6), and glutathione transferases M1 and T1 (GSTM1, and GSTT1), data on NAT2 gene polymorphisms obtained from the current meta-analysis do not support a major association with PD risk, except in Asian populations.
|
27216438 |
2016 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease.
|
15174030 |
2004 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Further, cases carrying combination of heterozygous genotypes of CYP2D6*4 or CYP2D6*10A(188C > T) and NAT2*5 were found to be at significantly higher risk for PD demonstrating the importance of gene-gene interactions in determining susceptibility to PD.
|
20364044 |
2010 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, reports of associations between alleles of the CYP2D6 locus (nearby on 22q13) and IPD, although inconsistent, indicated that an IPD susceptibility locus might be in strong linkage disequilibrium with CYP2D6.
|
9630632 |
1998 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body disease.
|
9316701 |
1994 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetically slow CYP2D6 metabolizers are at higher risk for developing Parkinson's disease, a risk that increases with exposure to pesticides.
|
20345925 |
2010 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, other hypotheses have been suggested: impairment of neuronal CYP 2D6 expression, transient modification of CYP 2D6 phenotype, or linkage of CYP2D6 gene to the candidate gene locus directly involved in IPD.
|
8726540 |
1996 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impaired debrisoquine metabolism resulting from defects in the cytochrome P450 CYP2D6-debrisoquine hydroxylase gene has been shown to be associated with the development of Parkinson's disease (PD).
|
9613747 |
1998 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we suggest that CYP2D6*4 polymorphism does not confer susceptibility to PD in the Korean population.
|
11442888 |
2001 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast with the results from genotyping studies conducted among patients with an older age at onset, there were no significant differences in CYP2D6 allelic frequencies between young-onset PD cases and controls.
|
8710083 |
1996 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In summary, the lower CYP2D6 levels in PD cases may have reduced their ability to inactivate PD-causing neurotoxins contributing to their disease risk.
|
21958961 |
2012 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we show that the mitochondrially targeted CYP2D6 can efficiently catalyze MPTP-mimicking compounds, <i>i.e.</i> 2-methyl-1,2,3,4-tetrahydroisoquinoline, 2-methyl-1,2,3,4-tetrahydro-β-carboline, and 9-methyl-norharmon, suspected to induce PD in humans.
|
31113867 |
2019 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Individuals with a metabolic defect in the cytochrome P450 CYP2D6-debrisoquine hydroxylase gene with the poor metaboliser phenotype had a 2.54-fold (95% Cl 1.51-4.28) increased risk of Parkinson's disease.
|
1350805 |
1992 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson's disease.
|
15061826 |
2004 |